ConductScience.org, home

Paper17319909

Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Khorana AA and 4 others. J Thromb Haemost, 2007. Cited by 1,327 papers, by iCite.

Cite this record

ConductScience Library. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Papers, record 17319909. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17319909

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.
PubMed
Journal
J Thromb Haemost
PubMed
Year
2007
PubMed
Publication types
Comparative Study, Letter, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
1,327
iCite
Relative citation ratio, by iCite
31.3
iCite
Revised in PubMed
2023-08-29
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Khorana AAA A
2Francis CWC W
3Culakova EE
4Kuderer NMN M
5Lyman GHG H

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Ambulatory CareMajor topic
Antineoplastic AgentsMajor topic
NeoplasmsMajor topic
ThromboembolismMajor topic
Follow-Up Studies
Humans
Mortality
Population Surveillance
Prospective Studies
Time Factors
United States

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
1K23 CA120587NCI NIH HHSUnited StatesK23CA120587PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials4

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01853202EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot TrialBackgroundClinicalTrials.gov
NCT04294589Evaluation of NETs in Patients With Solid Cancers Associated With a High Risk of Venous Thromboembolic EventsBackgroundClinicalTrials.gov
NCT06196918Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma PatientsBackgroundClinicalTrials.gov
NCT07850453Vortosiran for VTE PreventionBackgroundClinicalTrials.gov

Download CSV of trials

Cited by742

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,327 citations.

PMIDTitleJournalYearIn PapersSource
42947797Knowledge, attitudes, and practices regarding venous thromboembolism prevention in patients with lung cancer.Front Public Health2026https://conductscience.org/library/papers/42947797PubMed
42912389Trends in Direct Oral Anticoagulant Use for Cancer-Associated Venous Thromboembolism.JAMA Netw Open2026https://conductscience.org/library/papers/42912389PubMed
42898415Role of four new blood coagulation tests in cancer stem cell-mediated tumor-related venous thromboembolism.Bioimpacts2026https://conductscience.org/library/papers/42898415PubMed
42897372Ferritin and LDH predict thrombotic risk beyond conventional scoring systems in DLBCL.Ann Hematol2026https://conductscience.org/library/papers/42897372PubMed
42761046Construction and verification of a nomogram to predict the probability of venous thromboembolism in lung cancer patients.Front Mol Biosci2026https://conductscience.org/library/papers/42761046PubMed
42751713
Characteristics of Cancer-Associated Thrombosis Based on Changes in Clinically Measurable Coagulation Factors and Coagulation/Fibrinolysis Markers in Patients with Cancer: A Multicenter Cross-Sectional Study.
Ann Vasc Dis2026https://conductscience.org/library/papers/42751713PubMed
42730163A Mitochondrial-Related Gene Signature for Diagnosis and Immune Microenvironment Modulation in Lung Cancer and Venous Thromboembolism.World J Oncol2026https://conductscience.org/library/papers/42730163PubMed
42699731Integrating pharmacovigilance and machine learning: bleeding signal detection and risk prediction for oral anticoagulants in cancer patients.Res Pract Thromb Haemost2026https://conductscience.org/library/papers/42699731PubMed
42653312Biomarkers of Hypercoagulability and Thromboinflammation in Cervical Cancer-Associated Thrombosis: A Systematic Review with Translational Insights from Breast Cancer.Int J Mol Sci2026https://conductscience.org/library/papers/42653312PubMed
42568708Temporal validation of the electronic health record cancer-associated thrombosis model in patients with low bleeding risk.Res Pract Thromb Haemost2026https://conductscience.org/library/papers/42568708PubMed
42566095Development and validation of a nomogram for predicting venous thromboembolism risk in colorectal cancer patients undergoing postoperative chemotherapy.Med Oncol2026https://conductscience.org/library/papers/42566095PubMed
42487960Development and validation of an interpretable machine learning model for venous thromboembolism risk prediction in patients with lung cancer: a real-world study.Front Med (Lausanne)2026https://conductscience.org/library/papers/42487960PubMed
42473469Venous mechanical thrombectomy for deep vein thrombosis in patients with cancer: a single-center prospective study.Blood Vessel Thromb Hemost2026https://conductscience.org/library/papers/42473469PubMed
42449662Hypercoagulability Predicts Survival and Reflects NET-Associated Thromboinflammation in Advanced Pancreatic Cancer.Cancers (Basel)2026https://conductscience.org/library/papers/42449662PubMed
42369044Clinical dose of enoxaparin enhances oncolytic virus M1 infection and antitumor efficacy in human bladder cancer.iScience2026https://conductscience.org/library/papers/42369044PubMed
42368860Preoperative cardiovascular evaluation in patients with cancer.Front Cardiovasc Med2026https://conductscience.org/library/papers/42368860PubMed
42319679Platelet-Prostate cancer crosstalk driving disparities and therapeutic vulnerabilities.Discov Oncol2026https://conductscience.org/library/papers/42319679PubMed
42308329Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation.Sci Transl Med2026https://conductscience.org/library/papers/42308329PubMed
42305777GLOBE: an explainable machine learning platform for preoperative prediction of thromboembolism and neurological deterioration in patients with glioma.Front Neurosci2026https://conductscience.org/library/papers/42305777PubMed
42295501Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis.Drug Saf2026https://conductscience.org/library/papers/42295501PubMed

See all 742 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17319909

GET https://conductscience.org/api/papers/v1/17319909/cited_by?page=2